Online-Ressource
PAGEPress Publications
;
2021
In:
Monaldi Archives for Chest Disease ( 2021-09-09)
In:
Monaldi Archives for Chest Disease, PAGEPress Publications, ( 2021-09-09)
Kurzfassung:
Ranolazine derives from piperazine and has been approved as a drug for the therapy of chronic stable angina. It acts by selectively inhibiting the late sodium inward current. Moreover, ranolazine has other metabolic features which makes it effective in other diseases as well as coronary artery ones. In this paper I make an updated review of all possible therapeutic roles of ranolazine: through cardiology and beyond.
Materialart:
Online-Ressource
ISSN:
2532-5264
,
1122-0643
DOI:
10.4081/monaldi.2021.1806
Sprache:
Unbekannt
Verlag:
PAGEPress Publications
Publikationsdatum:
2021
ZDB Id:
2375904-5
ZDB Id:
2375907-0
| Bibliothek |
Standort |
Signatur |
Band/Heft/Jahr |
Verfügbarkeit |
